Structural insights for HIV-1 therapeutic strategies targeting Vif

Trends in Biochemical Sciences

Volumn 39, Issue 9, 2014, Pages 373-380

  Salter, Jason D ^a   Morales, Guillermo A ^b   Smith, Harold C ^a,c  

^a OyaGen Inc   (United States)

^b Cogent Professionals ^*  (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

APOBEC; Core binding factor ; Cullin 5; Elongin B C; Viral infectivity factor

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN B EDITING CATALYTIC SUBUNIT LIKE 3; CORE BINDING FACTOR BETA; CULLIN; CULLIN 5; ELONGIN B; ELONGIN C; HUMAN IMMUNODEFICIENCY VIRUS 1 VIRAL INFECTIVITY FACTOR; UNCLASSIFIED DRUG; VIRUS PROTEIN; ANTIVIRUS AGENT; APOLIPOPROTEIN B MRNA EDITING ENZYME; CYTIDINE DEAMINASE; VIF PROTEIN;

CRYSTAL STRUCTURE; DIMERIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; CHEMISTRY; DRUG DESIGN; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIVIRAL AGENTS; CYTIDINE DEAMINASE; DRUG DESIGN; HIV INFECTIONS; HIV-1; HUMANS; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84906940147     PISSN: 09680004     EISSN: 13624326     Source Type: Journal    
DOI: 10.1016/j.tibs.2014.07.001     Document Type: Review

References (48)

1. Strebel K., et al. The HIV 'A' (sor) gene product is essential for virus infectivity. Nature 1987, 328:728-730.
2. Guo Y., et al. Structural basis for hijacking CBF-beta and CUL5 E3 ligase complex by HIV-1 Vif. Nature 2014, 505:229-233.
3. Hultquist J.F., et al. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 2011, 85:11220-11234.
4. Aydin H., et al. Structure-guided analysis of the human APOBEC3-HIV restrictome. Structure 2014, 22:668-684.
5. Fribourgh J.L., et al. Core binding factor beta plays a critical role by facilitating the assembly of the Vif-cullin 5 E3 ubiquitin ligase. J. Virol. 2014, 88:3309-3319.
6. Zhang W., et al. T-cell differentiation factor CBF-beta regulates HIV-1 Vif-mediated evasion of host restriction. Nature 2012, 481:376-379.
7. Schrofelbauer B., et al. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc. Natl. Acad. Sci. U.S.A. 2004, 101:3927-3932.
8. Kitamura S., et al. The APOBEC3C crystal structure and the interface for HIV-1 Vif binding. Nat. Struct. Mol. Biol. 2012, 19:1005-1010.
9. Bohn M.F., et al. Crystal structure of the DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-binding domain. Structure 2013, 21:1042-1050.
10. Comeau S.R., et al. ClusPro: a fully automated algorithm for protein-protein docking. Nucleic Acids Res. 2004, 32:W96-W99. (Web Server issue).
11. Kozakov D., et al. PIPER: an FFT-based protein docking program with pairwise potentials. Proteins 2006, 65:392-406.
12. Yang S., et al. The multimerization of human immunodeficiency virus type I Vif protein: a requirement for Vif function in the viral life cycle. J. Biol. Chem. 2001, 276:4889-4893.
13. Yang B., et al. Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. J. Biol. Chem. 2003, 278:6596-6602.
14. Miller J.H., et al. The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G. Retrovirology 2007, 4:81.
15. Barraud P., et al. Advances in the structural understanding of Vif proteins. Curr. HIV Res. 2008, 6:91-99.
16. Bernacchi S., et al. Importance of the proline-rich multimerization domain on the oligomerization and nucleic acid binding properties of HIV-1 Vif. Nucleic Acids Res. 2011, 39:2404-2415.
17. Techtmann S.M., et al. Hydrodynamic and functional analysis of HIV-1 Vif oligomerization. Biochemistry 2012, 51:2078-2086.
18. Gallerano D., et al. Biophysical characterization of recombinant HIV-1 subtype C virus infectivity factor. Amino Acids 2011, 40:981-989.
19. Auclair J.R., et al. Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity. Proteins 2007, 69:270-284.
20. Batisse J., et al. APOBEC3G impairs the multimerization of the HIV-1 Vif protein in living cells. J. Virol. 2013, 87:6492-6506.
21. Bergeron J.R., et al. The SOCS-box of HIV-1 Vif interacts with ElonginBC by induced-folding to recruit its Cul5-containing ubiquitin ligase complex. PLoS Pathog. 2010, 6:e1000925.
22. Wolfe L.S., et al. Dissection of HIV Vif interaction with the human E3 ubiquitin ligase. J. Virol. 2010, 84:7135-7139.
23. Donahue J.P., et al. The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation. Virology 2008, 377:49-53.
24. Giri K., et al. Molecular structure and biochemical properties of the HCCH-Zn2+ site in HIV-1 Vif. Biochemistry 2009, 48:7969-7978.
25. Marcsisin S.R., et al. On the solution conformation and dynamics of the HIV-1 viral infectivity factor. J. Mol. Biol. 2011, 410:1008-1022.
26. Moreira I.S., et al. Hot spots - a review of the protein-protein interface determinant amino-acid residues. Proteins 2007, 68:803-812.
27. Wells J.A., McClendon C.L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007, 450:1001-1009.
28. Lipinski C.A., et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 1997, 23:3-25.
29. Winter A., et al. Biophysical and computational fragment-based approaches to targeting protein-protein interactions: applications in structure-guided drug discovery. Q. Rev. Biophys. 2012, 45:383-426.
30. Sheehy A.M., et al. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418:646-650.
31. Keskin O., et al. Hot regions in protein-protein interactions: the organization and contribution of structurally conserved hot spot residues. J. Mol. Biol. 2005, 345:1281-1294.
32. Chiu Y.L., Greene W.C. The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu. Rev. Immunol. 2008, 26:317-353.
33. Conticello S.G., et al. Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol. Biol. Evol. 2005, 22:367-377.
34. LaRue R.S., et al. Guidelines for naming nonprimate APOBEC3 genes and proteins. J. Virol. 2009, 83:494-497.
35. Russell R.A., Pathak V.K. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J. Virol. 2007, 81:8201-8210.
36. He Z., et al. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J. Mol. Biol. 2008, 381:1000-1011.
37. Dang Y., et al. Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 virus Vif that regulate APOBEC3G and APOBEC3F neutralizing activity. J. Virol. 2010, 84:5741-5750.
38. Yamashita T., et al. Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F. Microbes Infect. 2008, 10:1142-1149.
39. Dang Y., et al. Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization. J. Virol. 2009, 83:8544-8552.
40. Siu K.K., et al. Structural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3F. Nat. Commun. 2013, 4:2593.
41. Pery E., et al. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. J. Virol. 2009, 83:2374-2381.
42. Albin J.S., et al. A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif. J. Biol. Chem. 2010, 285:40785-40792.
43. Smith J.L., Pathak V.K. Identification of specific determinants of human APOBEC3F, APOBEC3C, and APOBEC3DE and African green monkey APOBEC3F that interact with HIV-1 Vif. J. Virol. 2010, 84:12599-12608.
44. Dang Y., et al. Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity. J. Virol. 2010, 84:8561-8570.
45. Huthoff H., Malim M.H. Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation. J. Virol. 2007, 81:3807-3815.
46. Binka M., et al. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H. J. Virol. 2012, 86:49-59.
47. Zhen A., et al. A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity. J. Virol. 2010, 84:1902-1911.
48. Arnold K., et al. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 2006, 22:195-201.